Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer | Future Oncology
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer
Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer | SpringerLink
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma | PNAS
Progression free survival for patient with metastatic bone sarcoma... | Download Scientific Diagram
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer | SpringerLink
Table 3 from A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures - Spigel - 2018 -
Survival distributions for progression-free (PFS) and overall survival... | Download Scientific Diagram
Votrient - NPS MedicineWise
Clinical Trials | VOTRIENT® (pazopanib) tablets
Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial - Annals of Oncology
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update - ScienceDirect
The Impact of Pazopanib on the Cardiovascular System - Cody N. Justice, Mohamed H. Derbala, Tesla M. Baich, Amber N. Kempton, Aaron S. Guo, Thai H. Ho, Sakima A. Smith, 2018
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - ScienceDirect
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
Votrient - NPS MedicineWise
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study - Clinical Genitourinary Cancer
820-Renal cell metastatic pAZOPanib | eviQ
Votrient, pazopanib
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
